Kuznetsova O S, Tallerova A V, Nikitin S V, Kovalenko L P
V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
Bull Exp Biol Med. 2016 Feb;160(4):483-5. doi: 10.1007/s10517-016-3202-z. Epub 2016 Feb 23.
We studied the effects of SNK-411, a new 5-pyrimidinol derivative, on serum cytokine profile of C57Bl/6 mice with Lewis lung carcinoma. The compound was injected intraperitoneally in doses of 25 and 50 mg/kg. A significant (by 3.5 times) increase in serum IL-4 content was detected in mice with tumors on day 9 of tumor development. In mice receiving SNK-411 in doses of 25 and 50 mg/kg, IL-4 content significantly decreased (by 4.0 and 3.6 times) on days 2-8 of carcinoma development; IL-2 content decreased by 1.4 and 1.2 times and IL-6 content decreased by 2.7 and 1.6 times, respectively, in comparison with control mice with tumors. Injections of SNK-411 in the same doses on days 8-15 of carcinoma development led to a significant decrease in IL-4 levels (by 2.2 and 4.5 times, respectively, in comparison with control mice with tumors) and did not affect serum levels of other cytokines.
我们研究了新型5-嘧啶醇衍生物SNK-411对患有Lewis肺癌的C57Bl/6小鼠血清细胞因子谱的影响。该化合物以25和50mg/kg的剂量腹腔注射。在肿瘤发展的第9天，检测到荷瘤小鼠血清IL-4含量显著增加（增加3.5倍）。在接受25和50mg/kg剂量SNK-411的小鼠中，在癌发展的第2 - 8天，IL-4含量显著降低（分别降低4.0和3.6倍）；与荷瘤对照小鼠相比，IL-2含量分别降低1.4和1.2倍，IL-6含量分别降低2.7和1.6倍。在癌发展的第8 - 15天注射相同剂量的SNK-411导致IL-4水平显著降低（与荷瘤对照小鼠相比分别降低2.2和4.5倍），且不影响其他细胞因子的血清水平。
